Stockreport
Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today reported financial results for the quarter ended June 30, 2019 and provided an update on its clinical programs.“With the advancement of maralixibat into Phase 3, the expansion of the team and the successful completion of our initial public offering, 2019 has been a notable year for Mirum,” said Chris Peetz, president and chief executive officer of Mirum. “We are excited to have strengthened our capital position as we continue to build Mirum into a leading innovator in rare liver disease. We look forward to further advancing maralixibat and achieving our goal of offering children with cholestasis a new treatment option that targets bile acid overload, a primary driver of liver damage and pruritus in these progressive diseases.”Key Operational H
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..[MarketBeat]
- Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)[Business Wire]
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.[MarketBeat]
- Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $100.00 price target on by analysts at Leerink Partners.[MarketBeat]
- More
MIRM
SEC Filings
SEC Filings
- 12/8/25 - Form 8-K
- 12/5/25 - Form SCHEDULE
- 12/2/25 - Form 4
- MIRM's page on the SEC website
- More